Pharmaceutical

SK bioscience and Sanofi expand agreement for pneumococcal conjugate vaccines

SK bioscience and Sanofi have expanded their agreement to jointly develop pneumococcal conjugate vaccines (PCVs).

Dec 25, 2024 - 06:00
SK bioscience and Sanofi expand agreement for pneumococcal conjugate vaccines
SK bioscience and Sanofi have expanded their agreement to jointly develop pneumococcal conjugate vaccines (PCVs).
Read the original article

Tags:

Previous Article

FDA approves Lilly’s obesity med Zepbound to treat obstructive sleep apnoea

Next Article

Investors optimistic about continued biotech and medtech IPO resurgence in 2025

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Medicare taps acting official to head up its new drug price negotiations

STAT+: Medicare taps acting official to head up its new...

Jun 6, 2023

BMS reports 2% revenue loss in 2023 after Revlimid generics hurt sales

BMS reports 2% revenue loss in 2023 after Revlimid gene...

Feb 2, 2024

Health Canada approves Arcutis’ ZORYVE foam for seborrheic dermatitis 

Health Canada approves Arcutis’ ZORYVE foam for seborrh...

Oct 22, 2024